The Translational Initiative to Map Epigenetics in Aging (TIME-A)
Launched by ELYSIUM HEALTH · Feb 27, 2023
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The Translational Initiative to Map Epigenetics in Aging (TIME-A) study is designed to explore how our genes and lifestyle choices affect the way we age. The researchers want to learn more about the connections between our biological makeup, our daily habits, and our overall health as we get older. This study will help us understand why some people age differently than others and how we can promote healthier aging.
To participate in this study, you need to be at least 18 years old and have registered for an Index kit through the Elysium Health website. You will also need to give your permission to participate by signing a consent form. The study is currently not recruiting participants, but it will be open to everyone, regardless of gender. If you decide to join, you can expect to help advance important research on aging and health, which could benefit many people in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All adults aged 18 and above
- • Have registered at least one Index kit via the Elysium Health website
- • Able and willing to provide digital consent to the Research Consent Form, and the TIME-A Research Subject Consent Form
- Exclusion Criteria:
- • Consent to participate not given
About Elysium Health
Elysium Health is a biotechnology company dedicated to advancing health and longevity through the development of innovative supplements and therapies. With a strong emphasis on scientific research and collaboration with leading experts in the fields of biochemistry, genetics, and cellular biology, Elysium Health aims to translate groundbreaking discoveries into practical applications that enhance human health. The company’s clinical trials focus on investigating the efficacy and safety of its products, fostering a deeper understanding of the mechanisms underlying aging and age-related conditions. Elysium Health is committed to improving quality of life and promoting wellness across diverse populations through evidence-based solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Dayle Sampson, PhD
Principal Investigator
Elysium Health
Holly Holmes, PhD
Principal Investigator
Elysium Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials